nodes	percent_of_prediction	percent_of_DWPC	metapath
Brompheniramine—CYP2C8—Tazarotene—psoriasis	0.116	0.125	CbGbCtD
Brompheniramine—CYP2B6—Cholecalciferol—psoriasis	0.0656	0.0704	CbGbCtD
Brompheniramine—CYP2D6—Hydroxyurea—psoriasis	0.0523	0.0561	CbGbCtD
Brompheniramine—CYP2C8—Cholecalciferol—psoriasis	0.0497	0.0533	CbGbCtD
Brompheniramine—CYP2C8—Mycophenolate mofetil—psoriasis	0.0431	0.0462	CbGbCtD
Brompheniramine—CYP2C19—Cholecalciferol—psoriasis	0.0417	0.0447	CbGbCtD
Brompheniramine—CYP3A4—Calcitriol—psoriasis	0.0391	0.042	CbGbCtD
Brompheniramine—CYP2C9—Cholecalciferol—psoriasis	0.0347	0.0372	CbGbCtD
Brompheniramine—CYP2C8—Hydrocortisone—psoriasis	0.0346	0.0371	CbGbCtD
Brompheniramine—CYP2C8—Cyclosporine—psoriasis	0.0326	0.035	CbGbCtD
Brompheniramine—CYP2D6—Cholecalciferol—psoriasis	0.0317	0.034	CbGbCtD
Brompheniramine—CYP3A4—Methoxsalen—psoriasis	0.0304	0.0326	CbGbCtD
Brompheniramine—CYP2C19—Prednisone—psoriasis	0.0289	0.031	CbGbCtD
Brompheniramine—CYP2E1—Dexamethasone—psoriasis	0.0288	0.0309	CbGbCtD
Brompheniramine—CYP2B6—Dexamethasone—psoriasis	0.0284	0.0305	CbGbCtD
Brompheniramine—CYP2C19—Cyclosporine—psoriasis	0.0274	0.0294	CbGbCtD
Brompheniramine—CYP2C9—Cyclosporine—psoriasis	0.0228	0.0244	CbGbCtD
Brompheniramine—CYP2C8—Dexamethasone—psoriasis	0.0215	0.0231	CbGbCtD
Brompheniramine—CYP2D6—Cyclosporine—psoriasis	0.0208	0.0223	CbGbCtD
Brompheniramine—CYP3A4—Cholecalciferol—psoriasis	0.0201	0.0216	CbGbCtD
Brompheniramine—CYP2C19—Dexamethasone—psoriasis	0.018	0.0194	CbGbCtD
Brompheniramine—CYP3A4—Mycophenolate mofetil—psoriasis	0.0175	0.0187	CbGbCtD
Brompheniramine—CYP3A4—Triamcinolone—psoriasis	0.0175	0.0187	CbGbCtD
Brompheniramine—CYP2C9—Dexamethasone—psoriasis	0.015	0.0161	CbGbCtD
Brompheniramine—CYP3A4—Betamethasone—psoriasis	0.015	0.0161	CbGbCtD
Brompheniramine—CYP3A4—Prednisolone—psoriasis	0.0148	0.0159	CbGbCtD
Brompheniramine—CYP3A4—Hydrocortisone—psoriasis	0.014	0.015	CbGbCtD
Brompheniramine—CYP3A4—Prednisone—psoriasis	0.014	0.015	CbGbCtD
Brompheniramine—CYP2D6—Dexamethasone—psoriasis	0.0137	0.0147	CbGbCtD
Brompheniramine—CYP3A4—Cyclosporine—psoriasis	0.0132	0.0142	CbGbCtD
Brompheniramine—CYP3A4—Dexamethasone—psoriasis	0.00872	0.00936	CbGbCtD
Brompheniramine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000158	0.00232	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR ligand binding—CCL20—psoriasis	0.000156	0.0023	CbGpPWpGaD
Brompheniramine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000156	0.00229	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—HCAR2—psoriasis	0.000154	0.00227	CbGpPWpGaD
Brompheniramine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	0.000152	0.00223	CbGpPWpGaD
Brompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000145	0.00213	CbGpPWpGaD
Brompheniramine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000145	0.00212	CbGpPWpGaD
Brompheniramine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000144	0.00212	CbGpPWpGaD
Brompheniramine—HRH1—IL-4 Signaling Pathway—NFKB1—psoriasis	0.000143	0.0021	CbGpPWpGaD
Brompheniramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000143	0.00209	CbGpPWpGaD
Brompheniramine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	0.00014	0.00205	CbGpPWpGaD
Brompheniramine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000137	0.00201	CbGpPWpGaD
Brompheniramine—HRH1—IL-4 Signaling Pathway—STAT3—psoriasis	0.000128	0.00189	CbGpPWpGaD
Brompheniramine—KCNH2—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000126	0.00186	CbGpPWpGaD
Brompheniramine—CHRM2—SIDS Susceptibility Pathways—IL10—psoriasis	0.000123	0.00181	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—HCAR2—psoriasis	0.00012	0.00176	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—HCAR2—psoriasis	0.00012	0.00176	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—HCAR2—psoriasis	0.000119	0.00175	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—HCAR2—psoriasis	0.000118	0.00174	CbGpPWpGaD
Brompheniramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000118	0.00173	CbGpPWpGaD
Brompheniramine—KCNH2—SIDS Susceptibility Pathways—JUN—psoriasis	0.000117	0.00173	CbGpPWpGaD
Brompheniramine—KCNH2—SIDS Susceptibility Pathways—NFKB1—psoriasis	0.000113	0.00166	CbGpPWpGaD
Brompheniramine—HRH1—GPCR ligand binding—CCL20—psoriasis	0.00011	0.00162	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR ligand binding—CCL20—psoriasis	0.00011	0.00162	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR ligand binding—CCL20—psoriasis	0.00011	0.00161	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—HCAR2—psoriasis	0.000109	0.0016	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—HCAR2—psoriasis	0.000109	0.0016	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR ligand binding—CCL20—psoriasis	0.000109	0.0016	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—HCAR2—psoriasis	0.000108	0.00159	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—HCAR2—psoriasis	0.000107	0.00158	CbGpPWpGaD
Brompheniramine—KCNH2—SIDS Susceptibility Pathways—VEGFA—psoriasis	0.000103	0.00151	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—HCAR2—psoriasis	9.53e-05	0.0014	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—CCL20—psoriasis	9.22e-05	0.00135	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—HCAR2—psoriasis	9.12e-05	0.00134	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—CCL20—psoriasis	8.83e-05	0.0013	CbGpPWpGaD
Brompheniramine—KCNH2—SIDS Susceptibility Pathways—TNF—psoriasis	8.8e-05	0.00129	CbGpPWpGaD
Brompheniramine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	8.6e-05	0.00126	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—CCL20—psoriasis	8.38e-05	0.00123	CbGpPWpGaD
Brompheniramine—CHRM1—Circadian rythm related genes—LEP—psoriasis	8.37e-05	0.00123	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—TAGAP—psoriasis	8.26e-05	0.00121	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—NDUFA5—psoriasis	8.14e-05	0.0012	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—CCL20—psoriasis	8.02e-05	0.00118	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—TAGAP—psoriasis	7.91e-05	0.00116	CbGpPWpGaD
Brompheniramine—CHRM1—Circadian rythm related genes—NOS2—psoriasis	7.8e-05	0.00115	CbGpPWpGaD
Brompheniramine—CHRM1—Circadian rythm related genes—PPARG—psoriasis	7.29e-05	0.00107	CbGpPWpGaD
Brompheniramine—CHRM4—G alpha (i) signalling events—CXCL8—psoriasis	7.28e-05	0.00107	CbGpPWpGaD
Brompheniramine—KCNH2—SIDS Susceptibility Pathways—IL6—psoriasis	7.1e-05	0.00104	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—NDUFA5—psoriasis	7.01e-05	0.00103	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—CYP2S1—psoriasis	6.92e-05	0.00102	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—NDUFA5—psoriasis	6.86e-05	0.00101	CbGpPWpGaD
Brompheniramine—CHRM2—SIDS Susceptibility Pathways—CXCL8—psoriasis	6.72e-05	0.000987	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—HCAR2—psoriasis	6.44e-05	0.000946	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—HCAR2—psoriasis	6.42e-05	0.000943	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—HCAR2—psoriasis	6.4e-05	0.00094	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—HCAR2—psoriasis	6.34e-05	0.000931	CbGpPWpGaD
Brompheniramine—CHRM2—SIDS Susceptibility Pathways—JUN—psoriasis	6.25e-05	0.000918	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—CCL20—psoriasis	6.24e-05	0.000916	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—CCL20—psoriasis	6.22e-05	0.000913	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—CCL20—psoriasis	6.2e-05	0.00091	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—CCL20—psoriasis	6.14e-05	0.000902	CbGpPWpGaD
Brompheniramine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	6.07e-05	0.000892	CbGpPWpGaD
Brompheniramine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	6.05e-05	0.000889	CbGpPWpGaD
Brompheniramine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	6.03e-05	0.000886	CbGpPWpGaD
Brompheniramine—CHRM2—SIDS Susceptibility Pathways—NFKB1—psoriasis	6.02e-05	0.000884	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—CYP2S1—psoriasis	5.96e-05	0.000875	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—NDUFA5—psoriasis	5.93e-05	0.000871	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—CYP2S1—psoriasis	5.83e-05	0.000857	CbGpPWpGaD
Brompheniramine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	5.79e-05	0.00085	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—CCL20—psoriasis	5.67e-05	0.000832	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—CCL20—psoriasis	5.65e-05	0.000829	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—CCL20—psoriasis	5.63e-05	0.000827	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—TAGAP—psoriasis	5.59e-05	0.00082	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—CCL20—psoriasis	5.57e-05	0.000819	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—TAGAP—psoriasis	5.57e-05	0.000818	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—TAGAP—psoriasis	5.55e-05	0.000815	CbGpPWpGaD
Brompheniramine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	5.54e-05	0.000814	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.53e-05	0.000812	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—TAGAP—psoriasis	5.5e-05	0.000807	CbGpPWpGaD
Brompheniramine—CHRM2—SIDS Susceptibility Pathways—VEGFA—psoriasis	5.46e-05	0.000802	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—NDUFA5—psoriasis	5.29e-05	0.000777	CbGpPWpGaD
Brompheniramine—CHRM1—Circadian rythm related genes—JUN—psoriasis	5.17e-05	0.000759	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—CYP2S1—psoriasis	5.04e-05	0.000741	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—CCL20—psoriasis	4.95e-05	0.000727	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.94e-05	0.000725	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—NDUFA5—psoriasis	4.87e-05	0.000715	CbGpPWpGaD
Brompheniramine—CHRM2—G alpha (i) signalling events—CXCL8—psoriasis	4.84e-05	0.000711	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—NDUFA5—psoriasis	4.83e-05	0.000709	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—CCL20—psoriasis	4.74e-05	0.000696	CbGpPWpGaD
Brompheniramine—CHRM2—SIDS Susceptibility Pathways—TNF—psoriasis	4.68e-05	0.000687	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—CYP2S1—psoriasis	4.5e-05	0.000661	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.5e-05	0.000661	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR ligand binding—CXCL8—psoriasis	4.41e-05	0.000647	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR ligand binding—CXCL8—psoriasis	4.22e-05	0.00062	CbGpPWpGaD
Brompheniramine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	4.2e-05	0.000617	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—CYP2S1—psoriasis	4.14e-05	0.000608	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—CYP2S1—psoriasis	4.1e-05	0.000603	CbGpPWpGaD
Brompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.91e-05	0.000575	CbGpPWpGaD
Brompheniramine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.9e-05	0.000573	CbGpPWpGaD
Brompheniramine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.89e-05	0.000571	CbGpPWpGaD
Brompheniramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.85e-05	0.000566	CbGpPWpGaD
Brompheniramine—CHRM2—SIDS Susceptibility Pathways—IL6—psoriasis	3.78e-05	0.000555	CbGpPWpGaD
Brompheniramine—CHRM1—Circadian rythm related genes—TP53—psoriasis	3.41e-05	0.000501	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—CARM1—psoriasis	3.38e-05	0.000497	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CCL20—psoriasis	3.35e-05	0.000491	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CCL20—psoriasis	3.34e-05	0.00049	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CCL20—psoriasis	3.33e-05	0.000488	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CCL20—psoriasis	3.29e-05	0.000484	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—NDUFA5—psoriasis	3.18e-05	0.000468	CbGpPWpGaD
Brompheniramine—CHRM1—Circadian rythm related genes—IL6—psoriasis	3.12e-05	0.000459	CbGpPWpGaD
Brompheniramine—HRH1—GPCR ligand binding—CXCL8—psoriasis	2.98e-05	0.000438	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR ligand binding—CXCL8—psoriasis	2.97e-05	0.000436	CbGpPWpGaD
Brompheniramine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2.97e-05	0.000436	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR ligand binding—CXCL8—psoriasis	2.96e-05	0.000435	CbGpPWpGaD
Brompheniramine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2.96e-05	0.000435	CbGpPWpGaD
Brompheniramine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2.95e-05	0.000433	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR ligand binding—CXCL8—psoriasis	2.93e-05	0.000431	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—CARM1—psoriasis	2.91e-05	0.000427	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—CARM1—psoriasis	2.85e-05	0.000418	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—SOCS1—psoriasis	2.72e-05	0.0004	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—CYP2S1—psoriasis	2.71e-05	0.000398	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.64e-05	0.000388	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—SOCS1—psoriasis	2.61e-05	0.000383	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—TYK2—psoriasis	2.6e-05	0.000381	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—CXCL8—psoriasis	2.49e-05	0.000366	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—TYK2—psoriasis	2.49e-05	0.000365	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—CARM1—psoriasis	2.46e-05	0.000362	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—CXCL8—psoriasis	2.39e-05	0.00035	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.36e-05	0.000346	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.3e-05	0.000338	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—CXCL8—psoriasis	2.26e-05	0.000332	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—CARM1—psoriasis	2.2e-05	0.000323	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—CXCL8—psoriasis	2.17e-05	0.000318	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.15e-05	0.000316	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—CAT—psoriasis	2.08e-05	0.000305	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.05e-05	0.000302	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—CARM1—psoriasis	2.02e-05	0.000297	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—APOE—psoriasis	2.01e-05	0.000295	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—LEP—psoriasis	2.01e-05	0.000295	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—CARM1—psoriasis	2e-05	0.000294	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—APOE—psoriasis	1.93e-05	0.000283	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—LEP—psoriasis	1.93e-05	0.000283	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.87e-05	0.000275	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—NFKBIA—psoriasis	1.87e-05	0.000275	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—SOCS1—psoriasis	1.84e-05	0.000271	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—SOCS1—psoriasis	1.84e-05	0.00027	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—SOCS1—psoriasis	1.83e-05	0.000269	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—SOCS1—psoriasis	1.81e-05	0.000266	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—NFKBIA—psoriasis	1.79e-05	0.000263	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—CAT—psoriasis	1.79e-05	0.000263	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—TYK2—psoriasis	1.76e-05	0.000258	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—CAT—psoriasis	1.75e-05	0.000257	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—TYK2—psoriasis	1.75e-05	0.000257	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—TYK2—psoriasis	1.75e-05	0.000256	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—TYK2—psoriasis	1.73e-05	0.000254	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—CXCL8—psoriasis	1.68e-05	0.000247	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—CXCL8—psoriasis	1.68e-05	0.000247	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—CXCL8—psoriasis	1.67e-05	0.000246	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—CXCL8—psoriasis	1.66e-05	0.000243	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—APOE—psoriasis	1.62e-05	0.000237	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—TYK2—psoriasis	1.53e-05	0.000225	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—CXCL8—psoriasis	1.53e-05	0.000225	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—CXCL8—psoriasis	1.52e-05	0.000224	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—CXCL8—psoriasis	1.52e-05	0.000223	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—CAT—psoriasis	1.51e-05	0.000222	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—CXCL8—psoriasis	1.51e-05	0.000221	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—TYK2—psoriasis	1.47e-05	0.000216	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—PPARG—psoriasis	1.41e-05	0.000207	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—APOE—psoriasis	1.39e-05	0.000204	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—APOE—psoriasis	1.36e-05	0.0002	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—LEP—psoriasis	1.36e-05	0.0002	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—APOE—psoriasis	1.36e-05	0.0002	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—LEP—psoriasis	1.36e-05	0.000199	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—APOE—psoriasis	1.36e-05	0.000199	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—CAT—psoriasis	1.35e-05	0.000199	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—APOE—psoriasis	1.35e-05	0.000198	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—LEP—psoriasis	1.35e-05	0.000198	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—APOE—psoriasis	1.34e-05	0.000197	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—LEP—psoriasis	1.34e-05	0.000197	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—CXCL8—psoriasis	1.34e-05	0.000196	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—CARM1—psoriasis	1.32e-05	0.000194	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—CXCL8—psoriasis	1.28e-05	0.000188	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—IL6—psoriasis	1.27e-05	0.000187	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—NFKBIA—psoriasis	1.27e-05	0.000186	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—NFKBIA—psoriasis	1.26e-05	0.000186	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—NFKBIA—psoriasis	1.26e-05	0.000185	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—NFKBIA—psoriasis	1.25e-05	0.000183	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—CAT—psoriasis	1.24e-05	0.000183	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—JUN—psoriasis	1.24e-05	0.000182	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—CAT—psoriasis	1.23e-05	0.000181	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—IL6—psoriasis	1.22e-05	0.000179	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—PPARG—psoriasis	1.21e-05	0.000178	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—NFKB1—psoriasis	1.2e-05	0.000176	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—JUN—psoriasis	1.19e-05	0.000175	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—PPARG—psoriasis	1.19e-05	0.000174	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—APOE—psoriasis	1.18e-05	0.000173	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—NFKB1—psoriasis	1.14e-05	0.000168	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—VEGFA—psoriasis	1.09e-05	0.000159	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—STAT3—psoriasis	1.07e-05	0.000158	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—APOE—psoriasis	1.05e-05	0.000154	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—VEGFA—psoriasis	1.04e-05	0.000153	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—TYK2—psoriasis	1.04e-05	0.000152	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—TYK2—psoriasis	1.03e-05	0.000152	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—TYK2—psoriasis	1.03e-05	0.000151	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—STAT3—psoriasis	1.03e-05	0.000151	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—PPARG—psoriasis	1.03e-05	0.000151	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—TYK2—psoriasis	1.02e-05	0.00015	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—APOE—psoriasis	9.66e-06	0.000142	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—APOE—psoriasis	9.58e-06	0.000141	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—PPARG—psoriasis	9.15e-06	0.000134	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CXCL8—psoriasis	9.04e-06	0.000133	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CXCL8—psoriasis	9.01e-06	0.000132	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CXCL8—psoriasis	8.98e-06	0.000132	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CXCL8—psoriasis	8.89e-06	0.000131	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—IL6—psoriasis	8.59e-06	0.000126	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—IL6—psoriasis	8.57e-06	0.000126	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—IL6—psoriasis	8.54e-06	0.000125	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—IL6—psoriasis	8.46e-06	0.000124	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—PPARG—psoriasis	8.42e-06	0.000124	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—JUN—psoriasis	8.4e-06	0.000123	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—JUN—psoriasis	8.38e-06	0.000123	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—JUN—psoriasis	8.35e-06	0.000123	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—PPARG—psoriasis	8.34e-06	0.000123	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—JUN—psoriasis	8.27e-06	0.000121	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—TP53—psoriasis	8.2e-06	0.00012	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—CAT—psoriasis	8.13e-06	0.000119	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—NFKB1—psoriasis	8.09e-06	0.000119	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—NFKB1—psoriasis	8.06e-06	0.000118	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—NFKB1—psoriasis	8.04e-06	0.000118	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—NFKB1—psoriasis	7.96e-06	0.000117	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—TP53—psoriasis	7.85e-06	0.000115	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—IL6—psoriasis	7.5e-06	0.00011	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—VEGFA—psoriasis	7.34e-06	0.000108	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—VEGFA—psoriasis	7.32e-06	0.000107	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—VEGFA—psoriasis	7.29e-06	0.000107	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—STAT3—psoriasis	7.27e-06	0.000107	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—STAT3—psoriasis	7.24e-06	0.000106	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—VEGFA—psoriasis	7.22e-06	0.000106	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—STAT3—psoriasis	7.22e-06	0.000106	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—IL6—psoriasis	7.19e-06	0.000106	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—STAT3—psoriasis	7.15e-06	0.000105	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—APOE—psoriasis	6.32e-06	9.28e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—TP53—psoriasis	5.55e-06	8.15e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—TP53—psoriasis	5.53e-06	8.12e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—TP53—psoriasis	5.51e-06	8.09e-05	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—PPARG—psoriasis	5.5e-06	8.08e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—TP53—psoriasis	5.46e-06	8.01e-05	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—IL6—psoriasis	5.08e-06	7.46e-05	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—IL6—psoriasis	5.06e-06	7.43e-05	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—IL6—psoriasis	5.04e-06	7.41e-05	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—IL6—psoriasis	5e-06	7.34e-05	CbGpPWpGaD
